Navigation Links
Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
Date:5/28/2009

WAYNE, N.J., EMERYVILLE, Calif. and MELVILLE, N.Y., May 28 /PRNewswire-FirstCall/ -- Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets in combination with Tarceva(R) (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.

The SEARCH (Sorafenib and erlotinib, a randomized trial protocol for the treatment of patients with hepatocellular carcinoma) trial aims to further build on data from the Phase 3 SHARP trial, which demonstrated that Nexavar significantly extended overall survival in patients with unresectable liver cancer by 44 percent (HR=0.69; p-value=0.0006). Based on the strength of these data, Nexavar was approved for the treatment of patients with unresectable HCC in the United States and in Europe for the treatment of HCC. Nexavar is currently approved in more than 70 countries for the treatment of HCC, including China where more than half of all liver cancer cases worldwide occur each year.

"Nexavar is the only approved targeted therapy with efficacy and tolerability in liver cancer," said Dimitris Voliotis, MD, vice president, Nexavar Clinical Development, Bayer HealthCare Pharmaceuticals. "We look forward to seeing the potential of combining Nexavar with another effective cancer treatment, Tarceva, in treating this disease and further extending the lives of patients."

"This study will enable us to learn whether combining two oral targeted therapies, Nexavar and Tarceva, can improve survival in a disease that is difficult to trea
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.; OSI Pharmaceuticals; Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinsons Disease
2. The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation
3. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
4. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
5. National Medical Interpreter Certification Testing Enters Pilot Phase
6. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
7. Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
8. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
9. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
10. BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
11. Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Florida Hospital North Pinellas is being recognized ... Plus hospital. In order to receive the award, Florida ... all Get With The Guidelines - Stroke Quality Achievement ... achieved 75-percent or higher compliance with six of 10 ... are reporting initiatives to measure quality of care. ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 The ... has announced a scholarship for rising freshmen undergraduate students. ... leading periodontist office specializing in many periodontal procedures such ... treatment of gum disease . In honor of ... college scholarship for eligible rising freshmen undergraduate students. ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 ... company that provides vascular, echocardiogram and NCV testing ... be the preferred diagnostic testing provider for young ... coeducational public liberal arts university in Milledgeville, Georgia. ... Wimbledon U collegiate division, include a ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 "After studying the ... the benefits of prenatal spina bifida repair may outweigh the ... 35 to 40 range," says Fetal Care Institute Director ... maternal fetal medicine specialist. "The goal of the study ... for these mothers and their unborn babies." , Studies have ...
(Date:2/27/2015)... New York, NY (PRWEB) February 27, 2015 ... Cole Tickets for his "Forest Hills Drive Tour Act ... third album "2014 Forest Hills Drive" which debuted on the ... selling hip-hop album. In March, this accomplished hip-hop artist ... begins in early March and will visit cities such as ...
Breaking Medicine News(10 mins):Health News:Florida Hospital North Pinellas Receives Get With The Guidelines - Stroke Gold Plus Quality Achievement Award 2Health News:Nashville Periodontist Office AIOH Announces 2015 Scholarship 2Health News:Georgia College Ensures Student-Athletes Are Heart Smart Team Strong; Teams up with Wimbledon Health Partners to Offer Diagnostic Testing 2Health News:Georgia College Ensures Student-Athletes Are Heart Smart Team Strong; Teams up with Wimbledon Health Partners to Offer Diagnostic Testing 3Health News:Pregnant Women with a BMI above 35 Now Eligible for Fetal Spina Bifida Repair Surgery Study at the St. Louis Fetal Care Institute 2Health News:Pregnant Women with a BMI above 35 Now Eligible for Fetal Spina Bifida Repair Surgery Study at the St. Louis Fetal Care Institute 3Health News:J. Cole Tickets in Los Angeles, Mountain View, Chula Vista, New York, Chicago, Indianapolis, Holmdel, Dallas, Seattle, Camden, Bristow, Atlanta, Houston & Detroit On Sale 2Health News:J. Cole Tickets in Los Angeles, Mountain View, Chula Vista, New York, Chicago, Indianapolis, Holmdel, Dallas, Seattle, Camden, Bristow, Atlanta, Houston & Detroit On Sale 3
... Finding hints at new treatments for the disorder that ... (HealthDay News) -- A family in which the father ... held clues to treating the neurological disorder that can ... , By studying the family,s genome, researchers identified a ...
... this flu had new targets , WEDNESDAY, May 5 (HealthDay ... the World Health Organization has issued perhaps the most comprehensive ... definitive reference that shows in black-and-white what many people have ... a professor of medicine and of microbiology and immunology at ...
... ... answer one or two reader questions in the "By the Way, Doctor" feature. The newsletter,s ... ... of the Harvard Health Letter offers answers to readers, serious, whimsical, and just ...
... ... video conferencing is innovating the desktop by allowing video mobility whenever, wherever it is ... Brentwood, ... provider of video conferencing, audio visual integrations, managed services, and grant services, will be ...
... of Toronto have discovered a fundamentally new view of how ... enormously complex organs such as the brain. In a ... entitled "Deciphering the Splicing Code," a research team led ... of Toronto describes how a hidden code within DNA explains ...
... A recent study conducted at Northwestern Memorial Hospital found ... to a failure to understand all of the prescription ... admission. While it,s common for patients not to recall ... feeling well or being unexpectedly admitted to the hospital, ...
Cached Medicine News:Health News:Getting Closer to Cause of Tourette Syndrome 2Health News:Getting Closer to Cause of Tourette Syndrome 3Health News:H1N1 Often Hit the Young and Healthy 2Health News:H1N1 Often Hit the Young and Healthy 3Health News:Harvard Health Letter Features Q&As from Harvard Doctors 2Health News:Solutionz Conferencing & Polycom to Host Desktop Video Conferencing Webinar 2Health News:U of T researchers crack 'splicing code,' solve a mystery underlying biological complexity 2Health News:Patients presenting medication lists reduce the risk of error during hospital admission 2Health News:Patients presenting medication lists reduce the risk of error during hospital admission 3
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
(Date:2/27/2015)... Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... fourth quarter and full year ended December 31, 2014. ... PTC. We are now a growing commercial-stage biopharma company, ... rare disease space," stated Stuart W. Peltz, Ph.D., Chief ... bring the first treatment for Duchenne muscular dystrophy to ...
(Date:2/27/2015)... , Feb. 27, 2015  Chiasma, Inc., a ... product for the orphan condition acromegaly, today announced the ... Participants in the financing included new investors Rock Springs ... public investment fund, as well as existing investors MPM ... ARCH Venture Partners. Chiasma intends to ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... April 18, 2012 Financial executives in the medical ... and the burden of its related compliance costs will ... according to a survey conducted by KPMG LLP, the ... said their companies are already contemplating actions such as ...
... organiser UBM Live has revealed further details of ... CPhI Southeast Asia (SEA) 2012. Set to debut from 10-12 ... SEA is the first trade show and exhibition of its ... the ASEAN region. CPhI SEA will provide ...
Cached Medicine Technology:KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 2KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 3Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 2Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 3
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
20 GA TITANIUM RETINAL FORCEPS...
Medicine Products: